Alipay+ E-Wallet Partnerships Power iQIYI’s Fast Asia Expansion
Popular Asian e-wallets are helping iQIYI, a leading international streaming platform, accelerate its expansion through Alipay+ to help digital and entertainment (D&E) platforms reach young middle-class consumers looking for quality online video content.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005470/en/
More than 1 million consumers outside the Chinese mainland used Alipay+ partner e-wallets for subscription payments on iQIYI international app in 2022 (Photo: Business Wire)
Introduced by Ant Group in 2020, Alipay+ is a suite of cross-border digital payment, marketing and merchant digitalization solutions connecting global brands with mobile-savvy consumers worldwide, aimed at enabling businesses, particularly small and medium-sized enterprises, to process a wide range of mobile payment methods and reach more than 1 billion regional and global consumers.
Starting in 2021, iQIYI utilizes Alipay+ marketing solutions, such as Alipay+ Rewards and cashier-based marketing service, to reach potential consumers and improve transaction conversion rates in key markets. Developed by Alipay+ and partner e-wallets, Alipay+ Rewards is a new digital marketing platform that helps global brands engage better with consumers worldwide by offering incentives and exclusive services.
In 2022, more than 1 million consumers outside the Chinese mainland, mostly in Southeast Asia, used Alipay+ partner e-wallets, including TrueMoney (Thailand), GCash (The Philippines), DANA (Indonesia), Touch ’n Go eWallet (Malaysia) and Kakao Pay (South Korea) to pay for subscriptions or content on iQIYI’s international app.
In addition to these alternative payment methods, since 2023, Alipay+ has started offering customized marketing solutions through Alipay+ Rewards program to enable merchant partners to expand its market outreach efforts. On iQIYI’s international app, the number of new users making subscription payments through GCash, DANA and Touch ’n Go eWallet have increased respectively by 100 percent, 90 percent and 50 percent in March 2023, compared with the end of 2022.
The global over-the-top (OTT) market is expected to reach US$1,251 billion by 2027, representing a CAGR of 30 percent during 2021-20271. iQIYI ranks fifth among OTT platforms globally, and was named the top Asian OTT to watch Chinese-language, Thai and Malay dramas across major SEA markets.2
On April 18 in Bangkok, iQIYI kicked off its latest subscriber campaign for Southeast Asia by inviting hundreds of local fans to interact with leading casts of a popular TV series on its platform. The event was co-hosted by Alipay+ as one of its key e-wallet partners, TrueMoney, is popular in Thailand.
In April 2023, AlipayHK, the largest active e-wallet in Hong Kong SAR, China, became the latest Alipay+ partner wallet to support payment on iQIYI International App.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing solutions offered by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
About iQIYI
iQIYI, Inc. is a leading provider of online entertainment video services in China. It combines creative talent with technology to foster an environment for continuous innovation and the production of blockbuster content. It produces, aggregates and distributes a wide variety of professionally produced content, as well as a broad spectrum of other video content in a variety of formats. The Company distinguishes itself in the online entertainment industry by its leading technology platform powered by advanced AI, big data analytics and other core proprietary technologies. iQIYI attracts a daily subscriber base of more than 100 million, and its diversified monetization model includes membership services, online advertising services, content distribution, online games, IP licensing, talent agency, online literature, etc.
1
https://www.researchandmarkets.com/reports/5633245/over-the-top-ott-market-global-industry
2
https://www.screendaily.com/features/unpacking-the-recent-turnaround-success-of-chinese-streamer-iqiyi/5180170.article
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005470/en/
Contact information
Media Inquiries
Li Tao
Ant Group
tao.l@antgroup.com
Aggie Yu
iQIYI
aggieyu@qiyi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom